News

Microbiomes assessed as autoimmune triggers for RA


 

The autoimmunity that causes rheumatoid arthritis needs to start somewhere in the body, and prime candidates include mucosal surfaces, like the mouth, gut, and lungs. The idea is that various microbes that colonize or infect these surfaces and form local microbiomes may trigger pathophysiologic processes that end up causing an autoimmune reaction, which results in rheumatoid arthritis.

Perhaps the most advanced research along these lines has looked at the links between rheumatoid arthritis (RA) and periodontitis, and particularly links between RA and infection with Porphyromonas gingivalis, a periodontitis pathogen. Evidence accumulated from several different research groups worldwide points to ways by which periodontal infection or P. gingivalis could produce autoimmune reactions, and the case has become compelling enough to launch a clinical intervention study that tries to interrupt this etiology.

Courtesy Dr. Marjorie Jeffcoat

A study showed that 62% of new-onset RA patients and 53% with chronic RA had severe periodontal disease (shown here), compared with 22% of healthy controls.

"There is a good deal of evidence that the pattern of microbial colonization on mucosal surfaces contributes to autoimmunity, which probably also depends on underlying genetic predispositions," said Dr. Jerry A. Molitor, a rheumatologist at the University of Minnesota in Minneapolis. "I’m convinced there is a risk from periodontal infection for subsequent development of RA. Our data and multiple other data sets suggest that."

Dr. Molitor referred to epidemiologic data that he and his associates have analyzed from the nearly 16,000 Americans enrolled in Atherosclerosis Risk in Communities (ARIC), a cardiovascular-disease study that also collected data on RA and periodontitis as well as serum specimens. Their studies showed associations between periodontitis, development of antibodies to cyclic citrullinated peptides (CCPs), and later development of RA.

P. gingivalis is unique among oral bacteria in producing an enzyme capable of citrullinating human peptides and proteins.

"We see a very interesting association of immune responses to P. gingivalis and autoantibody expression" both in patients with RA and in those at high risk for developing RA, said Dr. Ted R. Mikuls, a rheumatologist at the University of Nebraska in Omaha. "We know that citrullinated proteins serve as targets for the autoimmunity that characterizes RA, so it’s very strong circumstantial evidence" for an etiologic relationship between P. gingivalis and RA, he said in an interview.

Results from a case-control study with 332 people that he published in 2012 showed that in those at high risk for developing RA, immunity to P. gingivalis was significantly associated with the presence of RA-related autoantibodies (Arthritis Rheum. 2012;64:3522-30).

A study of 31 new-onset RA patients, 34 chronic RA patients, and 18 healthy controls by a team of researchers at New York University showed that 62% of new-onset patients and 53% with chronic RA had severe periodontal disease, compared with 22% of the healthy controls (Arthritis Rheum. 2012;64:3083-94). Although indicators of exposure to P. gingivalis were similar in the new-onset RA patients and the other two subgroups, the new-onset patients showed unique exposures to Prevotella and Leptotrichia genuses, evidence implicating these bacteria as potential RA triggers.

Dr. Jerry A Molitor

A study of 50 patients with recently-diagnosed RA showed that 34% had immunoglobulin G antibody to P. gingivalis, often as anti-CCP antibody (Arthritis Res. Ther. 2013;15:R109). This subgroup also had significantly elevated levels of rheumatoid factor, a higher erythrocyte sedimentation rate, and a trend toward greater disease activity, reported Dr. Sheila L. Arvikar and her associates in a 2013 paper.

"Our work and those of others demonstrate that P. gingivalis seems to play a role in RA pathogenesis," said Dr. Arvikar, a rheumatologist at Massachusetts General Hospital in Boston. "I emphasize that it may only be important in a subset of patients. P. gingivalis antibodies and periodontal disease are not universal findings among RA patients. In other patients, different microbial pathogens and other sites may play more of a role, such as gut pathogens like Prevotella copri, or pathogens in the lungs and airways," she said in an interview.

Others agree that while the most study so far has been done on periodontitis and P. gingivalis, the range of other microbes that might be involved at mucosal sites in the mouth or elsewhere remains mostly unexamined.

"Is periodontitis the only risk factor? No. It’s probably a major player for a subset of patients, but RA is very heterogeneous," said Dr. Mikuls. "There are multiple pathways to the disease. Periodontitis is along at least one of those paths, but there are others."

Dr. Ted R. Mikuls

Evidence implicating P. copri came from a study with 114 people: 44 patients with new-onset and untreated RA, 26 with chronic RA, 16 with psoriatic arthritis, and 28 healthy controls (eLife 2013;2:e01202). Researchers used stool specimens to assess each person’s intestinal microbiome and found a high prevalence of Prevotella species in general and P. copri specifically in the patients with new-onset RA. Presence of P. copri linked with reduced levels of other bacterial types, including beneficial microbes, and results from a mouse study suggested that P. copri exerts proinflammatory effects.

Pages

Recommended Reading

No survival benefit to bisphosphonate in chemoresistant breast cancer
MDedge Internal Medicine
Consider small-fiber neuropathies in systemic lupus erythematosus
MDedge Internal Medicine
Ultrasound-guided synovial tissue biopsies appear safe, reliable in early arthritis
MDedge Internal Medicine
Best cost savings seen with RA treatment aimed at fastest remission
MDedge Internal Medicine
Newly recognized autoantibody found in blood sera years before RA diagnosis
MDedge Internal Medicine
Anti-CCP antibodies associated with increased mortality in RA
MDedge Internal Medicine
Standard cardiovascular risk models no good in rheumatoid arthritis
MDedge Internal Medicine
Methotrexate less risky for lungs in RA than previously thought
MDedge Internal Medicine
Dental infection didn’t raise rheumatoid arthritis risk
MDedge Internal Medicine
FDA: Stop prescribing combo drugs with high-dose acetaminophen
MDedge Internal Medicine